



Presentation	Supplier Name	Market Segment	Human Papilloma Virus (HPV)																		
			2008	2009	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 1 dose vial	Xiamen Innovax Biotech Co (China)	Gavi73 <sup>1</sup>														\$2.9000	\$2.9000	\$2.9000	\$2.9000	\$2.9000	\$2.9000
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 1 dose vial	Xiamen Innovax Biotech Co (China)	MICs5																\$2.9000	\$2.9000	\$2.9000	\$2.9000
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 1 dose vial	Xiamen Innovax Biotech Co (China)	MICs6																\$4.5000	\$4.5000	\$4.5000	\$4.5000
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 1 dose vial	Yuxi Zerun Biotechnology Co (China)	Gavi73																		\$2.8000	\$2.8000
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 1 dose vial	Yuxi Zerun Biotechnology Co (China)	MICs																		\$3.5000	\$3.5000
Bivalent Human Papilloma Virus (Types 16 and 18) vaccine - 2 dose vial	GlaxoSmithKline Biologicals (Belgium)	Gavi73 <sup>2</sup>						\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$4.6000	\$5.1800	\$5.1800	\$5.1800	\$5.1800	\$5.1800	\$5.1800
	GlaxoSmithKline Biologicals (Belgium)	GNI per capita < \$3,995 <sup>3</sup>														\$10.2500 - \$11.4000	\$10.2500 - \$11.4000	\$10.2500 - \$11.4000	\$10.2500	\$10.2500 - \$11.4000	\$10.2500 - \$11.4000
	GlaxoSmithKline Biologicals (Belgium)	GNI per capita > \$3,995 <sup>3</sup>														\$14.1400	\$14.1400	\$14.1400	\$14.1400	\$14.1400	\$14.1400
Quadravalent Human Papilloma Virus (Types 6, 11, 16 and 18) vaccine - 1 dose vial	Merck Sharpe and Dome Corp (USA)	Gavi73 <sup>2</sup>						\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000	\$4.5000
	Merck Sharpe and Dome Corp (USA)	MICs <sup>4</sup>										\$13.4000	\$13.4000	\$13.4000 - \$25.0000	\$13.4000 - \$25.0000	\$13.5000 - \$26.7500	\$13.5000 - \$26.7500	\$13.5000 - \$26.7500	\$13.5000 - \$26.7500	\$13.5000 - \$26.7500	\$13.5000 - \$26.7500
Ninevalent Human Papilloma Virus (Types 6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine - 1 dose vial	Merck Sharpe and Dome Corp (USA)	MICs7																		\$13.5000 - \$33.2500	\$13.5000 - \$33.2500

Data shows awarded price per dose in US\$ per product per supplier per calendar year, based on supply agreement.

Prices displayed are in response to tenders with FCA incoterms.

<sup>1</sup>Prices apply to Gavi-eligible and transitioned countries

<sup>2</sup>Prices apply to Gavi-eligible and transitioning countries as listed on Gavi's website at <https://www.gavi.org/types-support/sustainability/eligibility> and <https://www.gavi.org/types-support/sustainability/transition>

<sup>3</sup>Prices are applicable to the following non-Gavi Middle-Income Countries: Pacific Island Countries and Cape Verde

<sup>4</sup>Prices are applicable to the following non-Gavi Middle-Income Countries: Botswana, Maldives, Morocco, Seychelles and Turkmenistan.

5 Prices are applicable to the following non-Gavi Middle-Income Countries: Egypt, Algeria, Venezuela, Jordan, Tunisia, El Salvador, Lebanon, Eswatini, Fiji, Cape Verde, Dominica, Belize, Vanuatu, Maldives, Samoa, Tonga, Saint Lucia, Saint Vincent and the Grenadines, Grenada, Kosovo, Tuvalu, Micronesia

6 Prices are applicable to the following non-Gavi Middle-Income Countries: Iraq, Namibia, Libya, Serbia, Bulgaria, Costa Rica, Botswana, Jamaica, Gabon, Equatorial Guinea, Northern Macedonia, Mauritius, Suriname, Montenegro, Palau, Marshall Islands, Georgia

7. Prices are applicable to non-Gavi Middle-Income Countries. Conditions apply.

Updated 9th September 2025